Top Biotech Stocks To Buy Right Now

&l;p&g;Last month I found 37 mutual fund managers who have proved their skill (in my view) by outperforming the S&a;amp;P 500&a;nbsp;over the last decade by enough make a real difference for shareholders. Of these, 16 managers run funds that don&s;t charge a load and are still open to new investors.&a;nbsp; These are the managers I am using to&a;nbsp;demonstrate the results&a;nbsp;of investing with&a;nbsp;great managers when they are performing. The four managers I recommended at the end of June are off to a good start. But with a trade war looming, let&s;s make sure we have our money in the&a;nbsp;hands of the best managers.&l;/p&g;

&l;img class=&q;dam-image shutterstock wp-image-679141378 size-large&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/679141378/960×0.jpg?fit=scale&q; alt=&q;&q; data-height=&q;640&q; data-width=&q;960&q;&g; The greatest mutual fund managers. Shutterstock

&l;strong&g;Performance Review as of July 23, 2018&l;/strong&g;

&l;/p&g;&l;div class=&q;table-wrapper&q;&g;&l;table&g;&l;tbody&g;&l;tr&g;&l;th&g;Style&l;/th&g; &l;th&g;Fund&l;/th&g; &l;th&g;Symbol&l;/th&g; &l;th&g;Manager&l;/th&g; &l;th&g;July MTD Return&l;/th&g; &l;/tr&g;&l;tr&g;&l;td&g;Technology&l;/td&g; &l;td&g;Firsthand Technology Opportunities&l;/td&g; &l;td&g;TEFQX&l;/td&g; &l;td&g;Kevin Landis&l;/td&g; &l;td&g;3.42%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Biotech&l;/td&g; &l;td&g;Fidelity Select Biotech&l;/td&g; &l;td&g;FBIOX&l;/td&g; &l;td&g;Rajiv Kaul&l;/td&g; &l;td&g;4.48%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Healthcare&l;/td&g; &l;td&g;Delaware Healthcare I&l;/td&g; &l;td&g;DLHIX&l;/td&g; &l;td&g;Liu-Er Chen&l;/td&g; &l;td&g;3.22%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Global Mid-Cap&l;/td&g; &l;td&g;Oppenheimer Global Opportunities&l;/td&g; &l;td&g;OGIYX&l;/td&g; &l;td&g;Frank V. Jennings&l;/td&g; &l;td&g;3.24%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Benchmark&l;/td&g; &l;td&g;S&a;amp;P 500 ETF&l;/td&g; &l;td&g;SPY&l;/td&g; &l;td&g;&l;/td&g; &l;td&g;3.04%&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

Top Biotech Stocks To Buy Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

Top Biotech Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.62 million shares from the previous level of 9.79 million. Shares were last seen at $178.26, in a 52-week trading range of $153.56 to $201.23.

  • [By ]

    Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

  • [By Todd Campbell]

    Neulasta has been one of Amgen’s (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan’s (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta’s revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen’s market share? Read on to find out what’s at stake for these companies and their investors.

Top Biotech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

    Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

  • [By Keith Speights]

    Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ:NITE), Arbutus Biopharma (NASDAQ:ABUS), and Biogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here’s what you need to know.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.00 million shares from the previous 3.91 million. The stock recently traded at $346.90, within a 52-week range of $249.17 to $388.67.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.73 million shares from the previous 4.33 million. The stock recently traded at $291.92, within a 52-week range of $249.17 to $370.57.

  • [By Keith Speights]

    This has been a bad year for Biogen (NASDAQ:BIIB) so far — the biotech’s stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.

Top Biotech Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Ethan Ryder]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.

  • [By Todd Campbell]

    Spark Therapeutics (NASDAQ:ONCE) reported its hemophilia A drug significantly reduced bleeding events and the need for prophylactic factor VIII infusions, but investors sold shares on worry that the gene therapy’s safety could be a problem. Investors similarly headed for the exits with Rite Aid (NYSE:RAD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) after the former scuttled an attempt to sell itself and the latter secured a first-in-class FDA approval. Are these falling stocks worth buying?

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

Leave a Reply

Your email address will not be published. Required fields are marked *